Clifford Chance has advised Eurazeo Investment Manager on the financing granted to the international private equity fund Keensight Capital for the acquisition of Inke, S.A.U., a Spanish company leader in micronization of complex Active Pharmaceutical Ingredients (“APIs”) belonging to the Neuraxpharm pharmaceutical group.
The Clifford Chance financing team was led by Global Financial Markets Partner Rodrigo UrÃa and associate MarÃa Vispo.
